Table 4.
Concentrations of albumins, transferrin and transthyretin according to the basic clinical characteristics of the patients with IBD.
| Albumins (mg/mL) Me [Q1–Q3] |
Transferrin (mg/mL) Me [Q1–Q3] |
Transthyretin (ng/mL) Me [Q1–Q3] |
|
|---|---|---|---|
| Disease duration | |||
| <5 | 19.7 [13.4–42.0] | 1.3 [0.9–2.9] | 2.8 [2.3–3.1] |
| 5–10 | 12.6 [7.2–47.3] | 1.9 [1.0–5.2] | 3.0 [2.5–4.3] |
| >10 | 27.8 [12.8–51.5] | 1.3 [0.7–3.3] | 3.0 [2.6–3.3] |
| p-value | 0.4217 | 0.4213 | 0.2840 |
| Biology therapy | |||
| YES | 19.4 [10.3–46.7] | 1.3 [0.9–4.2] | 3.1 [2.6–3.3] |
| NO | 37.2 [13.8–63.9] | 1.5 [0.2–2.9] | 2.1 [1.9–3.1] |
| p-value | 0.0753 | 0.3086 | 0.01224 * |
| Surgery history | |||
| YES | 31.1 [12.1–47.2] | 2.1 [1.2–6.7] | 3.0 [2.5–3.3] |
| NO | 17.6 [9.6–47.6] | 1.3 [0.8–3.1] | 2.9 [2.4–3.2] |
| p-value | 0.5300 | 0.1164 | 0.6717 |
* Univariate analyses. Post hoc multiple comparisons. Albumins: remission vs. moderate, p = 0.0252; moderate vs. severe, NS; remission vs. severe, p = 0.0132. Transthyretin: remission vs. moderate, NS; moderate vs. severe, p = 0.1900; remission vs. severe, p = 0.0143.